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SY STEMIC lupus erythematosus (SLE) is a disorder with
a  wide  range  of  immunological  abnormalities.  The
results of the studies undertaken in the last decade
indicated  that  SLE  pathogenesis  was  mainly  con-
nected with the breakdown of the activation control
of B and T cells, generating humoral or cell-mediated
responses  against  several  self-antigens  of  affected
cells. The last studies demonstrate that the role of g d
T lymphocytes in autoimmune diseases can be espe-
cially  important.  Flow  cytometry  techniques  were
used to investigate the number and percentage of TCR
g d T  cells  and  their  most  frequent  subtypes  in
peripheral  blood  of  32  patients  with  SLE  and  16
healthy volunteers. We also correlated TCR  g d cells
number with the level of T CD3+, T CD4+, T CD8+, and
NK (CD16) cells (cytometric measurements) and SLE
activity (on the basis of clinical investigations). Our
studies were preliminary attempts to evaluate the role
of that minor T cell subpopulation in SLE.  Absolute
numbers of cells expressing g d TCR in most SLE blood
specimens were significantly lower than in the con-
trol group (P<0.006). However, since the level of total
T  cell population was also decreased in the case of
SLE, the mean values of the percentage g d T cells of
pan  T  lymphocytes  were  almost  the  same  in  both
analysed populations (7.1% vs 6.3%, respectively). In
contrast to Vd 2+ and Vg 9+ subtypes of pan g d T cells,
Vd 3+ T cells number was higher in SLE patients (20 3
10  cells/m l)  than  in  healthy  control  group  (2  3 2
cells/m l)  (P=0.001).  However,  we  found  no  differ-
ences between the numbers of pan g d T lymphocytes
and studied their subtypes in the patients with active
and inactive disease. These cell subpopulations were
doubled  in  the  treated  patients  with  immunosup-
pressive agents in comparison with untreated ones;
however, data were not statistically significant.  Our
study indicated that Vd 3+ subtype of g d T cells seems
to  be  involved  in  SLE  pathogenesis;  however,  we
accept  the  idea  that  the  autoimmunity  does  not
develop from a single abnormality, but rather from a
number of different events.
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Introduction
Systemic lupus erythematosus (SLE) is a disorder with
a  wide  range  of  immunological  abnormalities. The
disease  is  characterized  by  B  cell  activation  and
formation  of  autoantibodies  against  nuclear,  cyto-
plasmic and cell surface antigens.1,2 However, increas-
ing  evidence  indicates  a  critical  role  of  T  cells,
particular CD4+ cells in inducing B cell hyperactivity.3
On the other hand, insufficient suppressor cell activity
may be responsible for autoantibody overproduction.
Defective  concanavalin  A-induced  suppressor  cell
function4,5 and  suppressor/cytotoxic  responses  to
Epstein-Barr virus (EBV)6 have been demonstrated in
SLE patients. Most human mature T cells express  a b
T-cell  receptors  on  the  membrane  (TCR  a b )  in
association  with  the  signal  transduction  of  CD3
complex.  These  TCR  a b T  cells  are  the  central
lymphocytes  in  the  immune  system. They  provide
specific pathogen recognition and long-term memory
all within the context of distinguishing foreign from
self antigens.7
Subpopulation  of T-cell, which  expresses TCR  g d
receptors (g d T cells) was identified 15 years ago8,9
but its significance in immune response and patho-
genesis of different diseases is still poorly understood.
TCR  g d receptors represent a disulphide-linked het-
erodimer  composed  of  rearranged  g and  d chains
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Mediators of Inflammation, 8, 305–312 (1999)homologous  to the TCR  a b and Ig  heavy  and  light
chains, which contribute to specificity of T cells and B
cells.10 Human  g d T cells range from 1% to 15% of
peripheral blood lymphocytes and show a predilec-
tion for the red pulp of the  spleen and the  gastro-
intestinal  tract.11,12 g d T  cells  play  a  role  in  host
epithelial surface control and early stage engagement
in  immune  response  against  viruses,  bacteria  and
parasites before the recruitment of a b T cells.7 They
are  able  to  react  with  antigens  both  in  a  major
histocompatibility  complex  (MHC)  -restricted  and
MHC-unrestricted fashion.13
The  pathologic  relevance  of  g d cells  in  human
autoimmune diseases is suggested by their reactivity to
highly conserved stress proteins and by the accumula-
tion of g d T cells in affected organs.14–17 The possible
role of g d T cells in autoimmune disease is also raised
by their ability to recognise self antigens. Increased
percentages of TCR g d cells have been found in the
synovial  fluids  and  synovia  of  patients  with  active
rheumatoid arthritis.18,19 A number of studies suggest
that  g d T  cells  play  a  role  in  the  pathogenesis  of
systemic sclerosis.20,21 Increased numbers of g d T cells
have been found in perivascular areas of the skin and
bronchoalveolar lavage samples, especially in patients
with recently diagnosed disease. Clonal expansion of
TCR g d T cells has been also reported in the periphery
of patients with systemic lupus erythematosus (SLE).22
Furthermore, Volc-Platzer et al. described preferential
expansion  of Vg 2/Vd 2  subset  in  lesions  in  chronic
cutaneous lupus erythematosus.23
In the present study we measured the number of
total circulating TCR g d cells and their subpopulations
in 32 SLE patients and in 16 healthy volunteers using
monoclonal antibodies against pan-g d , Vd 2, Vd 3, Vg 9
chain regions and flow cytometry techniques. We also
correlated the number of  g d T cells with T CD3+, T
CD4+, T CD8+ and NK (CD16) cells and SLE activity.
Patients and methods
Patients
A total of 32 unselected patients with SLE, 30 women
and  two  men  all  fulfilling the 1982  revised  criteria
defined  by  the  American  Rheumatism  Association
(ARA)24 were included in our study. Their mean age
was  43.7  years  (range  22–65  years).  The  mean
duration  of  the  disease  was  84.2  months  (range  3
months  to  28  years). Ten  patients  had  never  been
treated with steroids or any other immunosuppressive
agents, 22 patients had been treated with prednisone
and  two  of  them  with  azatioprine  for  some  time
during the course of their disease, but 12 of them had
not been treated for at least 4 weeks before the g d T
cell population analysis.
We included both patients with active and inactive
disease  into  the  study.  Disease  activity  was  scored
during a visit to the outpatient clinic according to the
method described by Liang et al.25 Each patient was
assessed on two separate occasions, 2–4 weeks apart.
The  system  of  Systemic  Lupus  Activity  Measure
(SLAM) includes 24 clinical manifestations and eight
laboratory  parameters. The  maximum  score  in  this
system amounts to 84 points. In our group of patients,
the points ranged from 6 to 26. We considered the
score  of  0–10  points  indicative  of  inactive  disease,
and  a  score  of  over  10  points  indicative  of  active
disease.  This  decision  was  based  on  our  previous
observations26,27 that patients with score 10 had no
clinical  symptoms  of  active  disease  such  as  photo-
sensitivity,  fever,  polyarthritis,  serositis,  an  elevated
erythrocyte sedimentation rate or a high antinuclear
antibody level (ANA). A  similar distinction  between
active  and  inactive  disease  was  also  performed  by
other  authors.28 Our  group  of  patients  included  9
patients  with  inactive  and  23  patients  with  active
disease. The  clinical  and  laboratory  features  of  SLE
patients are presented in Table 1. The control group of
16 healthy volunteers was also studied. They were 12
women and 4 men, aged from 37 to 56 years (mean 48
years). Each underwent a through physical evaluation
by one of the authors (ER).
Laboratory tests
On the day of blood sampling for T cells immunophe-
notyping, the following laboratory parameters were
analysed: complete blood cell count (CBC), erythro-
cyte  sedimentation  rate,  blood  urea  nitrogen  and
creatinine  levels,  fibrinogen  level,  partial  thrombo-
plastin  time  (PTT),  liver  function  tests  (GOT,  GPT,
bilirubin),  immunoglobulins  (IgG,  IgA,  IgM)  and
complement (C3, C4), urine and creatinine levels, and
anti-DNA antibodies. Chest X-rays and ECG were also
evaluated.
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Table 1. Clinical and laboratory characteristics of the patient
with SLE (symptoms according to Liang et al.
25
Symptom Number of
patients
%
Total 32 100
Active 23 71.8
Inactive 9 28.2
Fever 7 21.9
Arthritis 18 56.2
Skin symptoms 16 50.0
Reticuloendothelial system involvement 15 46.9
Pulmonary symptoms 4 12.5
Cardiovascular symptoms 16 50.0
Neurologic symptoms 19 59.4
Renal disorder (creatinine>1.3mg/dL) 2 6.2
Antinuclear antibodies 32 100.0
Anaemia (Hb<12g/dL) 11 34.4
Leukopenia (WBC<3.5(10
9/L) 9 28.1
Thrombocytopenia (PLT<150(10
9/L) 6 18.7
Raised ESR (>25mm/h) 29 90.6
Treatment with steroids during the study 22 68.7Immunophenotype analysis
Venous blood samples were collected at the time of
clinical assessment into pyrogen-free tubes, contain-
ing  anticoagulant  (EDTA  at  a  final  concentration  of
25 mM).  General  lymphocyte  immunophenotyping
and TCR diversity analysis were performed by stand-
ard  two-colour  immunofluorescence  measurement.
The  details  of  the  procedure  are  described  else-
where.29 Briefly a combination of phycoerythrin (PE)-
conjugated  and  fluorescein  isothiocyanate  (FITC)-
conjugated  monoclonal  (MoAbs)  was  used.  In
polystyrene tubes 100 m l of whole blood were directly
stained with 10 m l appropriate MoAbs in the dark at
room  temperature.  IgG1  isotype  control  antibody
conjugates  were  included  in  order  to  establish  the
background  fluorescence.  After  incubation  for
30 min, the samples were placed to Q-prep (Coulter)
for lysis of erythrocytes and fixation of nuclear cells.
At least 10,000 cells were then analysed on a Coulter
Epics-XL flow cytometer (Coulter, Hialeah, FL, USA).
Gate Check was used to gate lymphocyte population
defined by FS/SS and anti CD14 and CD45RO MoAbs.
Analysis was performed using XLv2 software.
Monoclonal antibodies
The direct staining of cells by monoclonal antibodies
(MoAbs) was performed. We were able  to use only
commercially  prepared  MoAbs  conjugated  with
proper  fluorochrome-PE-conjugated  UCHT1  (CD3+,
pan T),  IMMU510  (all  g d T  cells),  FITC-conjugated
13B8.2  (CD4+ T  cells),  B9.11  (CD8+ T  cells),  3G8
(CD16+,  mainly  NK  and  at  some  percentage  g d T
cells),  IMMU510  (all  g d T  cells),  IMMU389  (Vd 2,
specific domain of d chain TCR), P11.5B (Vd 3, specific
domain  of  d chain  TCR),  IMMU360  (Vg 9,  specific
domain  of  g chain  TCR),  were  all  supplied  by
Immunotech (A Coulter Company, USA). The anti-Vd 1
(Immunotech) was available as the plain proteins and
was not applied for staining in whole blood samples
together with other MoAbs. It was used for indirect
phenotyping of isolated lymphocytes. In these experi-
ments the goat/anti-mouse IgG (FITC and PE conju-
gated  F(2ab9 )2 fragments)  was  used  for
counterstaining.
Statistical analysis
The  analysis  of  the  results  indicated  that  normal
distribution  was  observed  for  almost  all  studied
variables. We presented our calculations as a mean ±
SD. The universal Mann–Whitney U test was used for
determination  of  differences  in  quantity  of  studied
cell populations. For phenotypic feature correlation
between studied T and NK cell populations, measured
simultaneously  in  the  same  patient,  we  used  the
Spearman rank  test.  Statistically  characteristic chan-
ges were considered at P<0.05.
Results
The  g d TCR  expression  on  peripheral  blood  T
lymphocytes  from  32  SLE  patients  and  16  healthy
donors has been determined using standard double-
colour immunofluorescence measurement. Their clin-
TCR g d cells in SLE
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Table 2. Characteristics of peripheral blood parameters in SLE patients and healthy donors (mean values ± SD and range in
parentheses)
Characteristic SLE patients Controls P value
N=32 N=16
Hb g/dL 12.4 ± 1.5 14.2 ± 1.5 NS
(9.7–17.3) (12.4–16.0)
Platelets (10
6/L) 194.0 ± 68.9 258.4 ± 89.9 0.005
(30.0–369.0) (156.5–426.4)
WBC/m l 4851.0 ± 2055.0 7148.0 ± 1635.0 0.008
(2320.0–10450.0) (5540.0–10100.0)
Pan T (CD3
+) cells/m l 630 ± 330 1025.0 ± 256.0 0.003
(170–1360) (603.0–1415.0)
T CD4
+ cells/m l 220 ± 140 500 ± 180 0.001
(440–570) (310–890)
T CD8
+ cells/m l 360 ± 230 450 ± 140 NS
(90–830) (200–620)
Ratio CD4
+/CD8
+ cells 0.77 ± 0.54 1.24 ± 0.21 0.005
(0.25–1.50) (0.56–1.70)
NK cells/m l 120 ± 100 290 ± 170 0.004
(10–770) (60–550)
Pan B (CD19
+) cells/m l 640 ± 540 530 ± 220 NS
(95–3760) (300–1020)ical data are summarised in Table 1. Detailed charac-
teristics of peripheral blood parameters, both for SLE
patients  and  for  the  healthy  donors,  are  shown  in
Table 2. The absolute numbers of WBC, pan T CD3+,
CD4+,  CD8+ cells  and  NK  cells  were  significantly
lower in  SLE patients than in the control group. In
contrast,  the  absolute  numbers  of  cytotoxic/sup-
pressor (CD8+ CD3+ ) and pan B (CD19+ ) cells in both
groups were similar.
The mean absolute values and percentages of g d T
cells and their subpopulations in peripheral blood of
SLE patients and in healthy individuals are presented
in Table 3. The mean absolute number of pan  g d T
cells was lower in SLE patients (40 ± 30/m l) than in
controls  (67  ±  39/m l)  (p=0.006).  However,  the
percentage of g d T cells of pan T cells was similar in
both groups (7.1% ± 6.5% and 6.3% ± 3.9%, respec-
tively) (P=0.7). A comparable decrease of circulating
Vd 2 and Vd 9 subtypes of pan g d T cells in SLE patients
(20 ± 10 cells/m l and 20 ± 20 cells/m l, respectively) in
relation to normal controls (50 ± 41 cells/m l and 49 ±
40  cells/m l,  respectively)  (P=0.003  and  0.005)  was
observed. On the other hand, the absolute number of
Vd 3+ subtypes of g d cells was significantly higher in
peripheral  blood  of  SLE  patients  (20  ± 10  cells/m l)
than in control donors (2 ± 21 cells/m l) (P= 0.001). A
similar difference was noted in the percentage of this
subpopulation in both groups (4.2% ± 5.7% vs 2% ±
0.1%,  respectively;  P=0.0003).  Although  the  above
calculated values for Vd 3+ cell subtypes were different
for particular SLE patients (see ranges and SD in Table
3), we found in patients blood specimens a distinct
positive correlation between peripheral blood abso-
lute numbers of g d T cells and the number of Vd 3+
cells  (R=0.85,  P=0.00001)  (Fig.  1). This  very  high
correlation coefficient for Vd 3+ lymphocytes provided
additional  strong  evidence,  that  this  g d T  subtype
could play some role in SLE activity.
It should be noticed that g d T cell levels practically
did not fluctuate if the analytical tests for particular
patients were repeated two or three times. However,
the  follow  up of  g d T  lymphocytes  changes  during
disease development were not done.
Data  presented  in  Table  3  showed  that  three-
quarters  of  pan  g d T  cells  in  the  blood  of  healthy
individuals  expressed  Vd 2  and  Vg 9  TCR  chains.
Although the above result was obtained in separate
staining measurements, we can univocally conclude
that the subfraction Vd 2/Vg 9 is the most frequent in
normal  blood,  as  stated  in  several  works.7 In  SLE
patients the proportion of Vd 2 and Vd 3 changed, but
the usage of Vg 9 in TCR structure is still high. In both
materials  the  percentage  of  the Vd 1  subpopulation
was low. As we mentioned in Patients and Methods,
the quantities of Vd 1+ were evaluated by the direct
staining method. It is known that there are discrep-
ancies  of  relative  cell  percentages  determined  by
direct and indirect staining procedures. We observed
2 cells/m l (0.4%) in SLE patients and 11 cells/m l (1.1%)
in healthy donors with Vd 1+ phenotype. These results
confirmed data which could be calculated from Table
3 (pan g d T cells minus Vd 2+ and Vd 3+ subfractions;
other unique Vd cells can be neglected). However, we
have decided to present only the results (Tables 3 and
E. Robak et al.
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Table 3. Analysis of g d TCR expression on circulating T cells of SLE patients and healthy donors (mean of cells number/m l ± SD
and range in parentheses)
Cell
Subpopulation
Number of g d cells/m l
SLE
Mean ± SD
(range)
Control
Mean ± SD
(range)
P value
Percentage g d T cells of pan T cells
SLE
Mean ± SD
(range)
Control
Mean ± SD
(range)
P value
Pan g d TCR
+ 40 ± 30 67 ± 39 0.006 7.1 ± 6.5 6.3 ± 3.9 0.7
(0–140) (19–154) (1.2–26.9) (1.5–13.1)
Vd 2 TCR
+ 20 ± 10 50 ± 41 0.003 3.6 ± 4.1 4.5 ± 3.6 0.03
(0–100) (3–147) (0.15–19.6) (0.3–12.5)
Vd 3 TCR
+ 20 ± 10 2 ± 2 0.001 4.2 ± 5.7 0.2 ± 0.1 0.0003
(0–100) (0–7) (0–21.4) (0.1–0.6)
Vg 9 TCR
+ 20 ± 20 49 ± 40 0.005 4.1 ± 4.6 4.1 ± 3.0 0.1
(0–110) (3–131) (0.4–21.2) (0.3–11.1)
FIG. 1. Correlation between pan g d
+ T cells number and the
number of Vd 3
+ cells in SLE patients.4) obtained by the same, more objective technique.
The  Vd 1+ fraction,  which  usually  increases  as  the
response against tumor antigens,10,13 did not play the
important role in our model.
No differences in g d T cells proportion as well as its
Vd 2, Vd 3 and Vg 9 subpopulations were observed in
patients  with  active  and  inactive  disease  (Table  4).
However, the absolute numbers of g d T cells and all
three analysed subtypes of these cells were 2 times
higher  in  patients  treated  with  immunosuppressive
drugs in comparison with untreated SLE patients. But
they were also not significantly different (Table 4).
Furthermore the absolute number g d T cells in SLE
specimens correlated positively with the total number
of T CD3+ cells (R= 0.44; P=0.02), but not with the
number of T CD4+ cells (R=0.31; P>0.05) or NK cells
(R=0.037; P>0.05) (Fig. 2). It  should be mentioned
that double-colour cytometric tests of pan g d T cells
did not allow us to detect CD8– and CD4– positive g d
T  lymphocytes.  This  observation  is  considered  in
detail in the Discussion section.
Discussion
According to our data the absolute numbers of cells
expressed g d TCR in most SLE blood specimens were
significantly  lower  (~40%;  P<0.006)  than  in  the
control group. However, since the level of total T cell
fraction (measured as CD3+ cells) was also decreased
in the case of SLE, the mean values of the percentage
g d T cells of pan T lymphocytes were almost the same
in both analysed populations (7.1% vs. 6.3%, respec-
tively).  Similar  observations  were  made  during  the
comparison of Vd 2+ and Vg 9+ subtypes of pan  g d T
cells.
The completely opposite result was obtained in the
case Vd 3+ T cells. The very low amount of them was
identified in peripheral blood of control donors (less
0.5% of pan T lymphocytes), but in specimens from
SLE patients their increase was very significant  and
concerning both the absolute number of cells and the
relative percentage value (20 vs. 2 cells, P<0.001 and
4.2% vs. 0.2%, P<0.0003, in SLE and healthy donors,
respectively). The diversity of the Vg region in TCR
formation  during  disease  development  seems to  be
less important. The separate problem is the expres-
sion of co-repressors (CD4 and CD8) on studied cells.
They  are  very  important  for  normal  a b T  cell
function. We suspected that our observations in the
case  of  CD4  antigen  (lack  of  expression)  were
correct,  but  we  did  not  exclude  that  CD8-negative
staining  was  false,  caused,  in  part,  by  instrument
limitations. We suspect that pan g d T cells in control
blood  specimens  were  CD8-negative;  however,  in
peripheral blood of SLE patients at least some of pan
g d T  cells  weakly  expressed  CD8  antigen,  as  an
activation  effect  of  cells  involved  in  autoimmune
response (data not shown).
Our observation concerning Vd 3+ cells’ expansion
in  SLE  patients  is  the  first  demonstration  that  this
subset of g d T lymphocytes seems to be involved in
SLE pathogenesis. Previously published data indicated
the increase of pan g d T cells in peripheral blood from
patients  with  this  disease.30,31 Other  works  charac-
terised expanded subtypes as the polyclonal Vd 1+ and
Vd 2+ or Vg 2/Vd 2+ oligoclonal  subsets.23 These  dis-
crepancies probably  arose as  the  result  of different
features  of  analysed  disease  in  particular  groups  of
patients, and indicated that changes of several para-
meters are involved in the disease development
However,  our  results  are  to  some  extent  unex-
pected, because most of the studies undertaken so far
indicate that total levels of pan g d T cells (calculated
both  as  the  cell  number/m l  and  as  the  relative
percentage of pan T CD3+ lymphocyte fraction) were
significantly  higher  in  peripheral  blood  of  patients
with  autoimmune  diseases  than  in  healthy  donors.
Janadi et al.32 observed the expansion CD4+ CD29+
g d T cells in the peripheral blood and synovial fluid of
patients with rheumatoid arthritis (RA). The elevation
of pan g d T cells in the same materials of RA patients
was  stated  by  Keystone  et  al.3 It  was  also  demon-
TCR g d cells in SLE
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Table 4. The frequency of  g d T cell subtypes in peripheral blood of patients with SLE dependent on disease activity and
immunosuppressive treatment (mean of cells number/m l ± SD and range in parentheses)
Cell
Subpopulation
SLE activity
Active
N=23
Inactive
N=9
P value
Immunosuppressive treatment
Treated
N=22
Untreated
N=10
P value
pan g d TCR
+ 41 ± 38 47 ± 49 NS 49 ± 45 27 ± 24 NS
(4–125) (14–146) (4–146) (6–79)
Vd 2 TCR
+ 19 ± 24 26 ± 27 NS 24 ± 28 13 ± 11 NS
(1–99) (4–70) (1–99) (4–33)
Vd 3 TCR
+ 22 ± 29 28 ± 29 NS 28 ± 31 14 ± 18 NS
(0–108) (5–90) (0–108) (2–52)
Vg 9 TCR
+ 21 ± 26 29 ± 27 NS 27 ± 29 15 ± 15 NS
(1–107) (4–82) (2–107) (3–45)strated in many investigations that the involvement of
g d T lymphocytes in the pathogenesis of autoimmune
diseases was most likely, because their expansion was
always significant. It has been discussed in the studies
concerning coeliac disease,34 multiple sclerosis,17,35
autoimmune  thyroid  diseases,36 autoimmune  liver
disease37 and  systemic  sclerosis.20 However,  in  the
cases of the above-specified diseases, the accumula-
tion of  g d T cells occurred predominantly in patho-
logically changed tissues; their increases in peripheral
blood of the same patients were less evident or even
unnoticeable. We feel obliged to say that our study of
peripheral blood cells was dictated by the pragmatic
goal to find a simple, highly standardised test for some
aspects of SLE diagnosis. Of course, we knew that the
cell representation in blood was only the approximate
image of the actual situation in affected tissues, but
the  reciprocal  circulation  of  T  lymphocytes  in  an
organism could allow the description of real changes
in  g d T  cells, as it  is  observed  in  tumor  infiltrating
lymphocytes  and  peripheral  circulation  cell
populations.10
In  the case of our SLE  patients investigation, the
decrease  of  pan  g d T  cells  number  (and  similar
events  for Vd 2+ and Vd 9+ subtypes)  partly  resulted
from  general  pan T  lymphopenia,  which  was  more
intensive  than  in  other  SLE studies. Another reason
for that phenomenon could be connected with the
capacity of g d T lymphocytes to very strong infiltra-
tion  and  pathological  damage  of  target  tissues,  as
skin  and  kidneys.  Such  accumulation,  particularly
Vg 2/Vd 2  TCR  expressed  cells,  was  observed  in
disease-damaged skin  of patients with chronic cuta-
neous lupus erythematosus23 and SLE.22 Probably in
our case  the Vd 3+ subfraction responded to  autolo-
gous  immune  antigens. The  persistent  treatment  of
the most patients with glucocorticoids could be also
responsible  for the  lower  numbers of  g d T  cells in
peripheral blood from SLE individuals than in speci-
mens  from  control  donors.  Several  published  data
demonstrated  that  long-continued  immunosuppres-
sive therapy determined the disappearance of expan-
ded g d T cell subset, in both target tissues, and the
peripheral  blood  of  patients  with  polymyositis  or
other  autoimmune  diseases.30,38 Spinozzi  et  al.31
demonstrated  data  obtained  from  in  vitro experi-
ments  that  all T  lymphocytes  bearing  the  g d TCR
(isolated both from SLE patients and healthy individ-
uals)  were  susceptible  to  dexamethasone,  and  ster-
oid-induced apoptosis was basic mechanism respon-
sible for cells death. They also demonstrated that  6
month  glucocorticoids  treatment  normalised  the
increased SLE g d T cell subfraction in blood, simulta-
neously  with  clinical  remission  of  the  disease
symptoms.
In our studies the analyses of immunosuppressive
treatment  influence  on  g d T  cell  level  were  not
such  univocal.  In  all  cell  subtypes  their  amounts
were  two times  higher in  the treated patients than
in  untreated  ones  (but  always  lower  than  in  speci-
mens of control donors). It  could be considered as
a  reconstruction  process  of  the  initial  g d T  cells
status,  typical  for  normal  blood.  A  relatively  low
number  of  studied  cases  can  be  responsible  for
statistical  doubts.  The  reason  why  it  was  also
observed for Vd 3+ T cells, which seem to compose
the unique subtype in  healthy individuals’ blood, is
unclear.  A  simple  look  at  the  data  presented  in
Table  4  may  lead  to  the  conclusion  that  the  fre-
quencies  of  total  g d T  cells  and  their  particular
subtypes  in  SLE  patients  were  not  generally  deter-
mined  by  disease  activity,  evaluated  according  to
the method of Liang  et al.25 But statistically impor-
tant,  objective  data  could  probably  be  obtained
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FIG. 2. Correlations between the number of pan g d
+ T cells
and the number of CD3
+, CD4
+ and NK cells in peripheral
blood of SLE patients.during the analysis of affected tissues. We registered
the  cell  distribution  in  peripheral  blood,  which
probably  reflected only some functional  tendencies
occurring  in  tissues. The  correlation  between  SLE
activity  and  concentrations  of  some  cytokines  and
their  soluble  receptors  was  detected  in  our  pre-
vious investigations.26,27
Data  from  Table  2  and  Figure  2  indicate,  that
although  absolute  amounts  of  pan T  CD3+ cells, T
helper  CD4+ cells  and  NK  cells  were  significantly
reduced in SLE patients, variations of T CD4+ and NK
cells were not correlated with changes of pan  g d T
cells. In such case the influence (if any) of compared
cell  populations  on  SLE  development  is
independent.
At present there is little known about the function
of  g d T  cells  in  SLE  pathogenesis.  The  recent
experiments confirm that they really play a significant
role  in  autoimmunity  regulation  in  vivo,  but  some
authors  published  contrary  data,  suggesting  g d T
lymphocytes’  responsibility  for  down-regulation  of
autoimmune diseases.5,36 The work of Peng et al.39
was the first demonstration in vivo that mice with g d
T  cells  deficiency  (TCRd -/-MRL/lpr)  developed  a
significantly more severe lupus-like disease and their
mortality  was  twice  that  in  normal  MRL/lpr  mice.
However,  g d T  lymphocytes  caused  also  down-
regulation of the  a b T cell response to infection and
thus  they  could  intensify  the  autoaggressive  testis
inflammation  evoked  by  Listeria infection.40 Addi-
tionally it was shown that g d T cells promoted the B
cell mediated autoimmunity.41
All  the  above  observations  may  indicate  that
different subtypes (or distinct clones) of g d T lympho-
cytes  realise  separate,  sometimes  even  opposite
functions  in  induction  of  autoreactive  immune  res-
ponses, for example in SLE. It should be noted that
their function is realised very early in ontogeny, and
further  disturbances  of  several  metabolic  pathways
can  change  the  final  effects.  We  believe  that  the
indicated  observations  do  not  reflect  epiphenome-
nons, but univocal evidence of it has to be verified by
additional experiments. We have initiated our future
studies  based  on  more  cases,  included  cytometric
analysis with cells isolated from affected tissues and
proper controls. We have also extended our studies
for  molecular  tests  (RT-PCR  detection  of  g d TCR
discret,  minor  subpopulations,  characterisation  of
their  genomic  structure  and  determination  of  clon-
ality  of  expanded  g d T  cells  subtypes).  Our  study
indicated that Vd 3+ subtype of g d T cells seems to be
involved in SLE pathogenesis; however, we accept the
view that the autoimmunity does not develop from
single  abnormality,  but  rather  from  a  number  of
different events.
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